Susceptibility of Vertilmicin to Modifications by Three Types of Recombinant Aminoglycoside-Modifying Enzymes
Min Yuan(National Institute for Communicable Disease Control and Prevention), Xuefu You(Chinese Academy of Medical Sciences & Peking Union Medical College), Shan Cen(Jewish General Hospital), Xinyi Yang(University of Sussex), Shuyi Si(Chinese Academy of Medical Sciences & Peking Union Medical College), Guoqing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Xixiong Kang(Capital Medical University), Congran Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Hui Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian‐Dong Jiang(Ningbo University)
Cited by 4
Related Papers
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
|Cancer Cell|2005|368
Berberine reduces insulin resistance through protein kinase C–dependent up-regulation of insulin receptor expression
|Metabolism|2008|265
Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation
|Theranostics|2019|185
Loss of Epigenetic Control of <i>Synuclein-γ</i> Gene as a Molecular Indicator of Metastasis in a Wide Range of Human Cancers
|Cancer Research|2005|179
Extracellular Signal-Regulated Kinase–Dependent Stabilization of Hepatic Low-Density Lipoprotein Receptor mRNA by Herbal Medicine Berberine
|Arteriosclerosis Thrombosis and Vascular Biology|2005|171